Aarti Pharmalabs Management Guidance Tracker
8 forward-looking guidance items tracked across 2 quarters.
Margins
Management reiterated standalone EBITDA growth guidance of 12-15% for FY26, supported by margin expansion and CDMO ramp-up.
Q3 FY26FY26 EBITDA flat to marginal growthActiveManagement expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali delays and API softness.
Revenue
CDMO segment expected to grow 35-40% YoY in FY26, driven by a strong order book and new capacities at Atali.
Q3 FY26CDMO revenue guidance for FY26 maintainedActiveManagement is confident of meeting the CDMO revenue guidance for FY26, though exceeding the target is now difficult due to project delays.
Expansion
Brownfield expansion from 5,000 to 9,000 MT per annum will be commissioned in phases during H2 FY26.
Q1 FY26Atali greenfield plant commercial production by end of Q2 FY26ActiveMechanical completion of Phase 1 at Atali is done; commercial production will commence towards end of Q2 FY26, with full ramp-up by end of FY26.
Q3 FY26Zanthin expansion mechanical completion by March 2026ActiveThe Zanthin expansion is on track for mechanical completion by end of March 2026, with incremental capacity available from Q1 FY27.